Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2015-03-24

Lead Sponsor: Craig A. Bunnell, MD, MPH

Target Recruit Count: 55

Registration Number: NCT00146588

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large Cell Lymphoma

Interventions: Drug: rituximab
Drug: doxorubicin
Drug: cyclophosphamide
Procedure: autologous stem cell transplantation

First Posted Date: 2005-09-05

Last Posted Date: 2015-09-02

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 128

Registration Number: NCT00144807

Locations: 🇫🇷
Polyclinique Bordeaux Nord, Bordeaux, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Hôpital Henri Mondor, Créteil, France

and more 10 locations

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Phase 3

Completed

Conditions: Diffuse Large-Cell Lymphoma

First Posted Date: 2005-09-01

Last Posted Date: 2011-03-04

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 380

Registration Number: NCT00140595

Locations: 🇧🇪
Groupe d'étude des lymphomes de l'adulte, Yvoir, Belgium
🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 7 locations

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

First Posted Date: 2005-08-30

Last Posted Date: 2012-03-29

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 6

Registration Number: NCT00138229

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Phase 2

Completed

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Velcade
Drug: Doxorubicin
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Vindesine
Drug: Bleomycin

First Posted Date: 2005-08-29

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 60

Registration Number: NCT00136565

Locations: 🇧🇪
Groupe d'Etude des Lymphomes de l'Adulte, Yvoir, Belgium
🇫🇷
Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷
Centre Hospitalier Robert Debré, Reims, France

and more 2 locations

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Large-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vindesine
Drug: Vincristine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2005-08-26

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 138

Registration Number: NCT00135499

Locations: 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭
Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪
Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium

and more 5 locations

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: Busulfan
Drug: Cyclophosphamide

First Posted Date: 2005-08-24

Last Posted Date: 2018-08-31

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 142

Registration Number: NCT00134017

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2005-08-24

Last Posted Date: 2015-10-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 210

Registration Number: NCT00134004

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Phase 2

Completed

Conditions: Lymphoma
Leukemia

Interventions: Biological: Filgrastim
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Methotrexate
Drug: Prednisone
Drug: Hydrocortisone
Drug: Vincristine
Drug: Leucovorin

First Posted Date: 2005-08-24

Last Posted Date: 2018-09-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 23

Registration Number: NCT00133991

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: KGEL vaccine
Biological: Filgrastim
Biological: Rituximab
Drug: Cyclophosphamide

First Posted Date: 2005-08-24

Last Posted Date: 2019-02-26

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 31

Registration Number: NCT00134082

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy